What the Retatrutide Trials Have Studied: Doses, Half-Life, and Escalation Protocols

Research context first

Retatrutide is an investigational compound. No approved dose, no labeled formulation, and no reconstitution standard exists outside the clinical trial setting. The information on this page describes what doses were administered in which trials, how those doses were escalated, and what pharmacokinetics the Phase 1b studies characterized. It is trial-design documentation — not a dosing guide, not a clinical recommendation, and not a protocol for any use outside a registered trial.

Every figure that follows is cited to a published study. The compound class here is investigational — every dosing reference is research-context only.

Retatrutide dosage

Clinical trials studied retatrutide across a dose range of 0.5 to 12 mg subcutaneous once weekly, with escalation schedules varying by trial.

Phase 1b (Urva et al., Lancet, 2022): doses of 0.5, 1.5, 3, 3/6, and 3/6/9/12 mg once weekly in a multiple-ascending-dose design over 12 weeks ^[4]. The escalation strategy (starting at 0.5 mg and stepping up across weeks) was designed to characterize tolerability before advancing to higher exposures.

Phase 2 obesity (Jastreboff et al., N Engl J Med, 2023): doses of 1, 4, 8, and 12 mg subcutaneous once weekly with built-in dose escalation to reach the assigned maintenance dose over the first several weeks ^[1]. Each escalation step was designed to allow GI tolerability to develop before advancing.

Phase 2 type 2 diabetes (Rosenstock et al., Lancet, 2023): 0.5-12 mg once weekly with stepwise escalation over 24-36 weeks, with placebo and active comparators ^[2].

The dose-response relationship was clear and consistent across trials: greater weight loss, greater glycemic improvement, and greater liver-fat reduction at higher doses — along with greater GI adverse event frequency. The 12 mg dose produced the largest efficacy signal and the most tolerability burden ^[1][2].

Why dose escalation matters: GLP-1 receptor-mediated slowing of gastric emptying is the primary driver of GI side effects. Starting at low doses and stepping up slowly allows the gut to adapt to reduced emptying rates before reaching maintenance exposure. In the trials, this was a protocol element built into the design. In unmonitored settings, there is no clinical oversight of escalation pace.

Retatrutide half life

Retatrutide has an approximately six-day half-life in human plasma, characterized in the Phase 1b trial ^[4]. This extended half-life results from the C20 fatty-diacid acylation chain on the peptide backbone, which binds to serum albumin and retards clearance — a pharmacokinetic engineering strategy also used in related long-acting incretin compounds.

The practical consequence is once-weekly dosing with steady-state concentration reached over approximately three to four weeks of repeated administration. The long half-life also means accumulation builds gradually, which is why GI side effects in the first weeks of the trials were generally less severe than at steady state — and why the trials used dose escalation to approach the target maintenance dose as tolerability improved.

Routes and formulation studied

All clinical trials studied retatrutide by subcutaneous injection — injection into the fatty tissue layer beneath the skin — administered once weekly. No oral, intravenous, intramuscular, or nasal formulation has been studied in published human trials.

Retatrutide was administered as a clinical-trial investigational product in pre-formulated vials under controlled manufacturing and storage conditions. No approved formulation, storage standard, or shelf-life specification exists for any non-trial preparation. The stability notes from the research record indicate the compound was studied only under clinical-grade conditions ^[4].

How to reconstitute retatrutide

This question has no valid answer outside a registered clinical trial. In the trials, retatrutide was supplied as a pre-formulated clinical-grade investigational product — not as a lyophilized (freeze-dried) powder requiring reconstitution. There is no published reconstitution protocol, validated diluent specification, or stability data for any non-trial preparation.

Gray-market research-labeled retatrutide is often sold as lyophilized powder with instructions citing bacteriostatic water at various concentrations. Those instructions are not derived from published trial protocols or any validated manufacturing standard. They are conventions borrowed from other research-peptide communities and applied to a compound whose identity and purity in gray-market supply is unverified ^[1][6].

The absence of a legitimate reconstitution protocol is a direct consequence of retatrutide's investigational status. It is not an information gap this site can fill.

How to store retatrutide

No published storage standard exists for any non-trial retatrutide preparation. In the trials, investigational product was managed under controlled clinical-grade storage and handling conditions specified by the manufacturer and trial protocol — conditions that are not replicated in any gray-market supply chain.

This is another consequence of the compound's investigational status: there is no approved label, no FDA-reviewed shelf-life specification, and no validated storage guidance applicable to anything outside the trial setting.

Retatrutide cost

Retatrutide is not commercially available and has no approved retail price. Participation in a registered clinical trial is free of charge to participants.

Gray-market research-labeled retatrutide sold online has ranged from several hundred to over a thousand dollars per vial in anecdotal reports from research-use communities, but these figures reflect an unregulated market with no quality controls. There is no licensed manufacturer, no standard concentration, and no pricing reference tied to verified product.

For context: approved relatives like semaglutide and tirzepatide have list prices in the hundreds of dollars per month in the United States. Retatrutide would be a separately priced product upon approval — no pricing has been announced by Eli Lilly as of mid-2026.